Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib and Ropeginterferon in Newly Diagnosed CML-CP
NCT07269470Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2026
- Primary completion
- Nov 2029
- Modality
- Fragment-Derived Small Molecules, Recombinant Proteins and Enzymes, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, ropeginterferon alfa-2b in chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2026; status: recruiting.
02
Drugs
dasatinibropeginterferon alfa-2b
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT07269470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07269470.